{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:25:33Z","timestamp":1794306333030,"version":"4.9.0"},"reference-count":34,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor condition that precedes multiple myeloma and related disorders but has also been associated with other medical conditions. Since systematic screening is not recommended, MGUS is typically diagnosed due to underlying diseases and most cases are not diagnosed. Most previous studies on MGUS disease associations have been based on clinical cohorts, possibly resulting in selection bias. Here we estimate this selection bias by comparing clinically diagnosed and screened individuals with MGUS with regards to demographics, laboratory features, and comorbidities. A total of 75,422 participants in the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study were screened for MGUS by serum protein electrophoresis, immunofixation and free light chain assay (clinicaltrials gov. Identifier: NCT03327597). We identified 3,352 individuals with MGUS, whereof 240 had previously been clinically diagnosed (clinical MGUS), and crosslinked our data with large, nationwide registries for information on comorbidities. Those with clinical MGUS were more likely to have at least one comorbidity (odds ratio=2.24; 95% confidence interval: 1.30-4.19), and on average had more comorbidities than the screened MGUS group (3.23 vs. 2.36, mean difference 0.68; 95% confidence interval: 0.46-0.90). They were also more likely to have rheumatological disease, neurological disease, chronic kidney disease, liver disease, heart failure, or endocrine disorders. These findings indicate that individuals with clinical MGUS have more comorbidities than the general MGUS population and that previous studies have been affected by significant selection bias. Our findings highlight the importance of screening data when studying biological and epidemiological implications of MGUS.<\/jats:p>","DOI":"10.3324\/haematol.2023.283191","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T03:59:48Z","timestamp":1689220788000},"page":"3392-3398","source":"Crossref","is-referenced-by-count":52,"title":["Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study"],"prefix":"10.3324","volume":"108","author":[{"given":"A\u00f0albj\u00f6rg \u00ddr","family":"Sigurbergsd\u00f3ttir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e6mundur","family":"R\u00f6gnvaldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigr\u00fan","family":"Thorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingiger\u00f0ur","family":"Sverrisd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u00f0r\u00fan \u00c1sta","family":"Sigur\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynjar","family":"Vi\u00f0arsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1ll Torfi","family":"\u00d6nundarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarni A.","family":"Agnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margr\u00e9t","family":"Sigur\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"\u00deorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cdsleifur","family":"\u00d3lafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sd\u00eds R\u00f3sa","family":"\u00de\u00f3r\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauti Kjartan","family":"G\u00edslason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"\u00d3lafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvar\u00f0ur J\u00f3n","family":"L\u00f6ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigur\u00f0ur Yngvi","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"55181","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13):1362-1369.","DOI":"10.1056\/NEJMoa054494"},{"key":"55182","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Katzmann JA, Kyle RA. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010; 375(9727):1721-1728.","DOI":"10.1016\/S0140-6736(10)60482-5"},{"key":"55183","doi-asserted-by":"crossref","unstructured":"Murray D, Kumar SK, Kyle RA. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019; 9(12):102.","DOI":"10.1038\/s41408-019-0263-z"},{"key":"55184","doi-asserted-by":"crossref","unstructured":"Weiss BM, Hebreo J, Cordaro DV. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol. 2014; 32(25):2699-2704.","DOI":"10.1200\/JCO.2013.50.0892"},{"key":"55185","doi-asserted-by":"crossref","unstructured":"Landgren O, Kyle RA, Pfeiffer RM. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22):5412-5417.","DOI":"10.1182\/blood-2008-12-194241"},{"key":"55186","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003; 102(10):3759-3764.","DOI":"10.1182\/blood-2003-03-0801"},{"key":"55187","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Pfeiffer RM, Bj\u00f6rkholm M. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010; 115(24):4991-4998.","DOI":"10.1182\/blood-2009-11-252072"},{"key":"55188","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012; 97(6):854-858.","DOI":"10.3324\/haematol.2011.054015"},{"key":"55189","doi-asserted-by":"crossref","unstructured":"Lindqvist EK, Goldin LR, Landgren O. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood. 2011; 118(24):6284-6291.","DOI":"10.1182\/blood-2011-04-347559"},{"key":"55190","doi-asserted-by":"crossref","unstructured":"Sigurbergsd\u00f3ttir A, Love TJ, Kristinsson SY. Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance. Front Immunol. 2022; 13:876271.","DOI":"10.3389\/fimmu.2022.876271"},{"key":"55191","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010; 116(15):2651-2655.","DOI":"10.1182\/blood-2010-04-282848"},{"key":"55192","doi-asserted-by":"crossref","unstructured":"Thorsteinsdottir S, Lund SH, Lindqvist EK. Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. Blood Adv. 2017; 1(27):2790-2798.","DOI":"10.1182\/bloodadvances.2017010454"},{"key":"55193","doi-asserted-by":"crossref","unstructured":"R\u00f6gnvaldsson S, Steingr\u00edmsson V, Turesson I, Bj\u00f6rkholm M, Landgren O, Kristinsson SY. Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. Haematologica. 2020; 105(11):2679-2681.","DOI":"10.3324\/haematol.2019.239632"},{"key":"55194","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Bj\u00f6rkholm M, Andersson TM. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica. 2009; 94(12):1714-1720.","DOI":"10.3324\/haematol.2009.010066"},{"key":"55195","doi-asserted-by":"crossref","unstructured":"Fermand JP, Bridoux F, Dispenzieri A. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018; 132(14):1478-1485.","DOI":"10.1182\/blood-2018-04-839480"},{"key":"55196","doi-asserted-by":"crossref","unstructured":"Bida JP, Kyle RA, Therneau TM. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009; 84(8):685-693.","DOI":"10.4065\/84.8.685"},{"key":"55197","doi-asserted-by":"crossref","unstructured":"Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990; 1(1):43-46.","DOI":"10.1097\/00001648-199001000-00010"},{"key":"55198","doi-asserted-by":"crossref","unstructured":"R\u00f6gnvaldsson S, Love TJ, Thorsteinsdottir S. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021; 11(5):94.","DOI":"10.1038\/s41408-021-00480-w"},{"key":"55199","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-e548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"55200","doi-asserted-by":"crossref","unstructured":"R\u00f6gnvaldsson S, Long TE, Thorsteinsdottir S, Love TJ, Kristinsson SY. Validity of chronic disease diagnoses in Icelandic healthcare registries. Scand J Public Health. 2023; 51(2):173-178.","DOI":"10.1177\/14034948211059974"},{"key":"55201","unstructured":"WHO. International statistical classification of diseases and related health problems, 10th revision (ICD-10). 2016."},{"key":"55202","unstructured":"R Core Team. R: a language and environment for statistical computing. 2019. Publisher Full Text|"},{"key":"55203","doi-asserted-by":"crossref","unstructured":"Kyle RA, Durie BGM, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24(6):1121-1127.","DOI":"10.1038\/leu.2010.60"},{"key":"55204","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346(8):564-569.","DOI":"10.1056\/NEJMoa01133202"},{"key":"55205","doi-asserted-by":"crossref","unstructured":"Turesson I, Kovalchik SA, Pfeiffer RM. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014; 123(3):338-345.","DOI":"10.1182\/blood-2013-05-505487"},{"key":"55206","doi-asserted-by":"crossref","unstructured":"Nasr SH, Satoskar A, Markowitz GS. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009; 20(9):2055-2064.","DOI":"10.1681\/ASN.2009010110"},{"key":"55207","doi-asserted-by":"crossref","unstructured":"Leung N, Bridoux F, Hutchison CA. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012; 120(22):4292-4295.","DOI":"10.1182\/blood-2012-07-445304"},{"key":"55208","doi-asserted-by":"crossref","unstructured":"Nasr SH, Valeri AM, Cornell LD. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012; 7(2):231-239.","DOI":"10.2215\/CJN.08640811"},{"key":"55209","doi-asserted-by":"crossref","unstructured":"Arnulf B, Bengoufa D, Sarfati E. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med. 2002; 162(4):464-467.","DOI":"10.1001\/archinte.162.4.464"},{"key":"55210","doi-asserted-by":"crossref","unstructured":"Andreone P, Zignego AL, Cursaro C. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998; 129(4):294-298.","DOI":"10.7326\/0003-4819-129-4-199808150-00005"},{"key":"55211","doi-asserted-by":"crossref","unstructured":"Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008; 111(7):3388-3394.","DOI":"10.1182\/blood-2007-10-121285"},{"key":"55212","doi-asserted-by":"crossref","unstructured":"KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021; 100(4s):S1-S276.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"55213","doi-asserted-by":"crossref","unstructured":"England JD, Gronseth GS, Franklin G. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2009; 1(1):5-13.","DOI":"10.1016\/j.pmrj.2008.11.010"},{"key":"55214","doi-asserted-by":"crossref","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022; 97(6):818-829.","DOI":"10.1002\/ajh.26569"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283191\/75823","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283191\/76331","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11154\/75823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:24Z","timestamp":1794045864000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283191","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}